Literature DB >> 32454773

Development and Validation of a Stability Indicating RP-HPLC Method for Simultaneous Estimation of Teneligliptin and Metformin.

Rajani Vetapalem1, Rajendra Prasad Yejella2, Lakshmana Rao Atmakuri3.   

Abstract

OBJECTIVES: The main objective of the present work is to develop a simple, precise, specific and stability method indicating reverse phase high performance liquid chromatography method for simultaneous estimation of teneligliptin and metformin in bulk and tablet dosage form.
MATERIALS AND METHODS: The analysis was performed with a Kromasil C18 column (250×4.6 mm, 5 μm) at 30°C using buffer: acetonitrile: methanol (65:25:10, v/v/v) as mobile phase. The detection was carried out with a flow rate of 1.0 mL/min at 254 nm.
RESULTS: The retention time of teneligliptin and metformin was 2.842 min and 2.017 min, respectively. The linearity range was 5-30 μg/mL for teneligliptin and 125-750 μg/mL for metformin. The forced degradation studies were performed as per the guidelines of the The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use under acidic, alkaline, oxidative, thermal, photostability, and neutral conditions.
CONCLUSION: This method was successfully validated for all the parameters and could detect the the correct amounts of active drug substance in formulations that are available in the market. This developed method in the present study could be successfully employed for the simultaneous estimation of teneligliptin and metformin in bulk and tablet dosage form. ©Copyright 2020 Turk J Pharm Sci, Published by Galenos Publishing House.

Entities:  

Keywords:  RP-HPLC; Teneligliptin; metformin; stability studies; validation

Year:  2020        PMID: 32454773      PMCID: PMC7227910          DOI: 10.4274/tjps.galenos.2018.16768

Source DB:  PubMed          Journal:  Turk J Pharm Sci        ISSN: 1304-530X


  2 in total

1.  Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

Authors:  Tomohiro Yoshida; Fumihiko Akahoshi; Hiroshi Sakashita; Hiroshi Kitajima; Mitsuharu Nakamura; Shuji Sonda; Masahiro Takeuchi; Yoshihito Tanaka; Naoko Ueda; Sumie Sekiguchi; Takayuki Ishige; Kyoko Shima; Mika Nabeno; Yuji Abe; Jun Anabuki; Aki Soejima; Kumiko Yoshida; Yoko Takashina; Shinichi Ishii; Satoko Kiuchi; Sayaka Fukuda; Reiko Tsutsumiuchi; Keigo Kosaka; Takahiro Murozono; Yoshinobu Nakamaru; Hiroyuki Utsumi; Naoya Masutomi; Hiroyuki Kishida; Ikuko Miyaguchi; Yoshiharu Hayashi
Journal:  Bioorg Med Chem       Date:  2012-08-17       Impact factor: 3.641

2.  Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes.

Authors:  Miyako Kishimoto
Journal:  Diabetes Metab Syndr Obes       Date:  2013-05-06       Impact factor: 3.168

  2 in total
  1 in total

1.  A ratiometric fluorescent sensor for detection of metformin based on terbium-1,10-phenanthroline-nitrogen-doped-graphene quantum dots.

Authors:  Masoud Gazizadeh; Gholamreza Dehghan; Jafar Soleymani
Journal:  RSC Adv       Date:  2022-08-10       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.